{"id":874395,"date":"2025-08-12T07:26:59","date_gmt":"2025-08-12T11:26:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-reports-financial-results-for-second-quarter-2025-and-provides-corporate-update\/"},"modified":"2025-08-12T07:26:59","modified_gmt":"2025-08-12T11:26:59","slug":"gain-therapeutics-reports-financial-results-for-second-quarter-2025-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-reports-financial-results-for-second-quarter-2025-and-provides-corporate-update\/","title":{"rendered":"Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update"},"content":{"rendered":"
\n

\n Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson\u2019s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated<\/em>\n <\/p>\n

\n Analysis of functional changes and biomarker activity at 90 days will be available during 4Q 2025 <\/em>\n <\/p>\n

\n In July 2025 following the close of 2Q 2025, Gain completed an underwritten public offering that resulted in approximately $7.1 million of net proceeds<\/em>\n <\/p>\n

BETHESDA, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update. Important highlights during the quarter included earlier-than-anticipated completion of target enrollment for the company\u2019s Phase 1b study evaluating lead candidate GT-02287 in Parkinson\u2019s disease with or without a GBA1 mutation. As a result, Gain expects the analysis of participants\u2019 functional changes scored according to the Movement Disorder Society Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS) and biomarker activity from cerebrospinal fluid at 90 days to be available during 4Q 2025.<\/p>\n

As of June 30, 2025, a total of 16 patients were enrolled in the Phase 1b study. However, enrollment has been kept open to any participants screened prior to July 31 who meet the criteria for the study. Total enrollment of the Phase 1b is not expected to exceed 20 participants. Additionally, the company recently submitted a request to extend the dosing duration of the Phase 1b study beyond the current 90 days allowable in the original protocol; an update on the status of that request is expected in the coming weeks.<\/p>\n

\u201cReaching target enrollment in the Phase 1b study of GT-02287 during 2Q 2025 was an exciting achievement for Gain and we look forward to reporting the analysis of both functional changes and biomarker activity during 4Q 2025, which will go a long way in planning the design of our Phase 2 clinical trial for GT-02287, an effort that has already begun in earnest,\u201d said Gene Mack, President and CEO of Gain. \u201cWe are further encouraged by clinicians\u2019 request to extend the screening window for participants by another month and their support to extend the dosing duration for participants in the study who wish to continue beyond the original 90-day dosing duration. We believe extending the dosing duration will also provide additional valuable feedback we can incorporate into our Phase 2 planning.\u201d<\/p>\n

Mr. Mack continued, \u201cWe are thankful not only to the clinicians but to the patients who have continued to express their desire to join this study or carry on as part of a potential dosing extension. The interest we have seen throughout the entirety of this study underscores the significant unmet need for a disease-modifying therapy for Parkinson\u2019s. We believe we are well-positioned to continue executing on our milestones, all with the goal of potentially shifting the treatment paradigm and delivering a life-changing treatment to those that need it.\u201d<\/p>\n

\n Second Quarter 2025 and Recent Corporate and Clinical Program Highlights<\/strong>\n <\/p>\n

\n Clinical Program Highlights<\/em>\n <\/p>\n